Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adaptor protein complex 2 subunit alpha-2 (AP2A2) is a large subunit of the AP-2 heterotetrameric adaptor protein complex, which is essential for clathrin-mediated endocytosis at the plasma membrane. AP2A2 binds polyphosphoinositide lipids to position the AP-2 complex at the membrane, serving as a platform for vesicle coat formation and as an interaction hub for accessory proteins. Through cargo recognition and endocytic vesicle assembly, AP2A2 is a key regulator of cellular protein internalization, synaptic vesicle recycling in neurons, and membrane trafficking in multiple tissues. Dysregulation or genetic variation in AP2A2 has been implicated in neurodegenerative conditions such as Alzheimer’s disease, and in other pathologies related to altered endocytosis and membrane trafficking. AP2A2 is not itself a direct therapeutic target but is of interest in studies of endocytic pathway dysfunction in disease.
Not applicable; AP2A2 is not a direct drug target. Its mechanism relates to endocytic vesicle coat assembly and cargo sorting. Drugs affecting endocytosis may alter AP2A2 function indirectly, but no explicit modulators are characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adaptor protein complex 2 subunit alpha-2 (AP2A2).